Halozyme plans finance $2.1 takeover of Evotech in cash: report
Halozyme Therapeutics (NYSE:HAL) intends to finance its 2B euro ($2.1B) proposed acquisition of Germany’s Evotec (EVO) in cash, Bloomberg reported Sunday, quoting Chief Executive Helen Torley. “We feel confident in being able to fund this as a fully cash deal,
Halozyme to Fund Proposed Evotec Takeover in Cash, CEO Says
Halozyme Therapeutics Inc. plans to finance its €2 billion ($2.1 billion) proposed takeover of Germany’s Evotec SE in cash, according to Chief Executive Officer Helen Torley. Most Read from BloombergSaudi Neom Gets $3 Billion Loan Guarantee From Italy Export Credit Agency SaceThe Urban-Rural Divide Over Highway Expansion and Emissions“We feel confident in being able to fund this as a fully cash deal,
Evotec shares surge 20% on Halozyme's 2 billion euro takeover bid
Halozyme Therapeutics (NASDAQ:HALO) announced on Thursday its plans to acquire German drug developer Evotec SE ADR (NASDAQ:EVO) in a deal valued at approximately 2 billion euros ($2.10 billion), to enhance its capabilities
Evotec surges on Halozyme takeover interest
Evotec surged on Friday after Halozyme Therapeutics confirmed it had submitted a non-binding proposal to buy the German biotech for €11.00 per share in cash, or about €2bn.
Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") confirmed it has submitted a non-binding proposal to the Management Board and Supervisory Board of Evotec SE (NASDAQ: EVO) ("Evotec") to acquire Evotec for €11.
Halozyme Proposes €2 Billion Acquisition of Evotec at €11 Per Share
Combination Would Create a Global Innovative Services Company with a Unique Set of Differentiated Technologies, a Deep Pipeline, and Best-in-class Industry Team Storage-Area Networking (SAN) DIEGO, Nov.
Halozyme says €2 billion takeover of Evotech would create leader in drug discovery
The stock of German drug-discovery and development company Evotech SE jumped 4% early Monday, after Halozyme Therapeutics Inc. offered an update on its non-binding takeover proposal at 11 euros a share in cash,
Halozyme: Fabless Or Not, The Stock Is Now A Steal On Evotec Deal
Halozyme's strategic acquisition of Evotec and innovative ENHANZE technology present growth opportunities. Click here for a ...
FierceBiotech5d
Halozyme offers $2B for Evotec to expand beyond delivery tech used by J&J and Roche
Buying Evotec would give Halozyme other revenue streams. Helen Torley, Halozyme’s CEO, explained the offer in a statement ...
Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion
Halozyme offers to acquire Evotec for €11.00 per share, boosting Evotec's value to €2 billion. The merger aims to enhance ...
腾讯网1d
奥洛兹美医疗(HALO.US)拟以21亿美元现金收购Evotech(EVO.US)
智通财经APP获悉，据外媒报道， 奥洛兹美医疗 (HALO.US)首席执行官海伦·托利 (Helen Torley)称，公司计划以现金形式融资20亿欧元 (合21亿美元)收购德国Evotec公司 ...
Reuters5d
Halozyme makes 2 billion euro buyout offer for drug developer Evotec
"The combination of Halozyme and Evotec would diversify and extend Halozyme revenue and EBITDA growth and durability well into the next decade and beyond," said Helen Torley, chief executive ...